Edgewise Therapeutics, Inc.
NASDAQ:EWTXBiotechnology
Healthcare
$41.37 +3.19%
+$1.11 today
- Market cap
- $4.45B
- Beta
- 0.30
- P/E (TTM)
- -21.9
- EPS (TTM)
- -$1.64
52W Low $12.15High $40.77
Volume 0.87M
Average 1.32M
EWTX Pre-Tax Margin
Income before tax as a percentage of revenue.
No reported Pre-Tax Margin figures are available to summarize.
Pre-Tax Margin history
Percent of revenue · from the income statement
No Pre-Tax Margin data reported for this period type.
Pre-Tax Margin vs competitors
How EWTX compares with its peers on the latest reported figures
EWTX Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 1.1% | +8.5 pp | +42.0 pp | |
| LTM Jun 2026 | -6.6% | -44.4 pp | +124.3 pp | |
| LTM Mar 2026 | -533.2% | -560.2 pp | +811.0 pp | |
| LTM Mar 2026 | -2878.3% | -2892.1 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding EWTX) | -269.9% | -302.3 pp | +124.3 pp | |
Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.27M |
| Gross Profit | 0 | 0 | 0 | 0 | (2.27M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 32.19M | 54.03M | 90.91M | 126.97M | 151.39M |
| Selling, General & Admin | 11.03M | 17.63M | 23.45M | 31.87M | 40.02M |
| Operating Expenses | 43.22M | 71.66M | 114.36M | 158.83M | 189.14M |
| Depreciation & Amortization | 272K | 538K | 1.73M | 2.29M | 2.27M |
| EBITDA | (42.54M) | (63.08M) | (98.43M) | (131.52M) | (165.53M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.22M) | (71.66M) | (114.36M) | (158.83M) | (191.41M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 402K | 2.66M | 14.19M | 25.02M | 23.61M |
| Interest Expense | 0 | 4.02M | 0 | 0 | 0 |
| Other Income / Expenses | 402K | 4.02M | 14.19M | 25.02M | 23.61M |
| Income Before Tax | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.81M) | (67.64M) | (100.16M) | (133.81M) | (167.8M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| EPS (Diluted) | (0.86) | (1.26) | (1.57) | (1.45) | (1.63) |
| Weighted Avg Shares | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
| Weighted Avg Shares (Diluted) | 49.5M | 53.59M | 63.72M | 92.41M | 102.93M |
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
Intrinsic Alpha fair value
Locked
Current Price
$41.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.